News

Sermonix Pharmaceuticals’ study “Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2− Breast Cancer With an ESR1 Mutation.” The clinical trial is ongoing in the United States, and Exactis is currently performing a feasibility assessment across Canada to identify sites interested in participating in the study, if interested please contact...
Exactis is pleased to be working with Dr. Sébastien Perreault from CHU Ste-Justine on the TRAM-01 study, “ Phase 2 study of Trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway”. This study is led by Dr. Sébastien Perreault and the...
Our new manuscript “Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition” is now available in Clinical Proteomics. Our research identified potential protein candidates for a blood-based prognostic signature of response to crizotinib in NSCLC patients harboring ALK fusion. https://doi.org/10.1186/s12014-020-9269-6 (Feb 2020) Publication: https://www.exactis.ca/2020/02/07/discovery-of-a-putative-blood-based-protein-signature-associated-with-response-to-alk-tyrosine-kinase-inhibition/
Dear Exactis Network,  With the current and ever-evolving situation with COVID-19, we wanted to provide you with an update on our response to date and our commitment moving forward. The health, safety and well-being of participants, and our Network Team is a top priority. We are following the lead of Canadian and provincial public health authorities at this time and...
Exactis Innovation is pleased to award $1M CDN to catalyze clinical research on innovative precision oncology therapeutics in Canada. This grant will support a multi-centre clinical trial in the Exactis research network comprising eleven premier cancer care institutions across Canada. The grant is awarded to a research team led by...
The TRICIA Study, a research project pairing molecular data with artificial intelligence, was awarded funding of $1.6 million this week by the Biopharmaceutical Research Consortium CQDM, the Ministère de l’Économie et de l’Innovation of the Government of Quebec, and the Canadian Cancer Society. Dr. Mark Basik of the Jewish General...
We are pleased to share an article on Precision Oncology and the Exactis PMT initiative appearing on www.personalhealthnews.ca, and printed in the April 2019 edition of Maclean’s Magazine, as part of a Mediaplanet special interest “Advancements in Cancer Care & Rare Disease” campaign. “Precision oncology is about selecting the right...
Exactis Innovation is pleased to formally announce the launch of the Exactis Innovation Investigator-Initiated Trial (IIT) Grant Competition. In alignment with the Exactis Mission to accelerate precision oncology by matching specific molecular or clinical profiles to novel treatments available through clinical trials, the Exactis IIT Grant Competition will provide $CDN...
MRM Proteomics Inc. is partnering with Exactis Innovation to develop and validate a clinical proteomic test that will provide clinicians and scientists with the ability to identify immune signatures and tumour mutation profiles to better match patients with the most effective treatments. The novel diagnostic test will be the first...
1 2 3